r&d expenses for the quarter were $ 55 million , an increase of 10 % or on a constant - currency basis , an increase of 7 % .
and that 's where resmed competes for more than 90 % of our business .
to be clear , the spectrum of chronic diseases that we look out here at resmed are , of course , including our core focus areas of sleep apnea , copd , and asthma , but it also includes biological systems interaction with cardiovascular disease , with cancer , with type 2 diabetes , with neuromuscular disease , alzheimer 's and beyond .
we now have over 8 billion nights of respiratory medical data in our cloud - based air solutions platform .
we have sold over 13.5 million 100 % cloud connectable medical devices into the market from resmed , and we have over 15 million patients enrolled in our airview solutions in the cloud .
r&d expenses as a percentage of revenue was 6.9 % compared to 6.8 % in the prior year .
even in countries like china , in our large asia region , where we saw the sharpest declines at the start of this crisis with very severe lockdowns in asia and particularly in china , we 're now back to already seeing around 70 - plus percent , 70 % to 75 % of pre-covid patient flow coming through the mainly hospital clinics in our china market .
we have an exciting pipeline of innovative solutions that will generate both medium and long - term value for our customers , with an industry - leading ip portfolio , including over the 6,000 patents and designs .
we recognized that restructuring expenses of $ 13.9 million associated with the closure .
depreciation and amortization for the december quarter totaled $ 41 million .
during the second quarter of fiscal - year 2021 , we generated over $ 170 million of cash , allowing us to return over $ 57 million in dividends to shareholders .
we were able to pivot our whole team and our hot business to provide over 150,000 ventilators during the peak needs of the pandemic and get them to where they needed based upon a humanitarian epidemiology model .
at december 31 , we had $ 826 million in gross debt and $ 570 million in net debt .
on a non-gaap basis , saas revenue increased by 5 % .
our board of directors today declared a quarterly dividend of $ 0.39 per share , reflecting the board 's confidence in our strong liquidity position and operating performance .
before i hand the call over to brett for his remarks , and then we get to the q&a , i want to once again express my sincere genuine gratitude to the more than 7,500 resmedians , whose perseverance , hard work , and dedication during the incredibly challenging circumstances of 2020 allowed our partners in healthcare to save the lives of many hundreds of thousands of people around the world with emergency need for ventilation , literally given the gift of breath and the gift of life to many during covid .
